Skip to main content

Novo Nordisk reveals significant increase in operating profit last year


NEW YORK Danish drug maker Novo Nordisk reported Friday that it increased its operating profit by 38% last year thanks to gross margin improvement and sales of modern insulins.

Sales of modern insulins increased by 28%, while sales of NovoSeven and Norditropin increased by 14% and 12%, respectively. Overall sales in North America increased by 18%, while international sales increased by 21%.

Meanwhile, gross margin improved by 1.7%, to 77.8%, primarily reflecting continued productivity improvements and a currency exchange rate effect of about 0.5%.

This ad will auto-close in 10 seconds